CHILDREN'S ZYRTEC ALLERGY (cetirizine hydrochloride) by Dr. Reddy's Laboratories is mechanism of actions cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral h 1 receptors. First approved in 2004.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
Children's Zyrtec Allergy is an oral chewable tablet formulation of cetirizine hydrochloride, a selective peripheral H1-receptor antagonist indicated for allergic conditions in pediatric patients. It works by inhibiting histamine-mediated allergic responses with negligible central nervous system penetration, making it suitable for children requiring non-sedating allergy relief.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition focus toward generic defense or line extensions.
Mechanism of Actions Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via selective inhibition of peripheral H 1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of animal and human models. In vivo…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fed Condition
Cetirizine Hydrochloride Tablets, 10 mg Bioequivalence Study of Dr.Reddy's Under Fasting Condition
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions
Worked on CHILDREN'S ZYRTEC ALLERGY at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWith zero linked job postings and LOE approaching, this product offers limited growth career opportunities and instead represents a consolidation or transition role for pharma professionals. Career development on Children's Zyrtec would focus on defending market share against generics, optimizing cost structures, and managing the shift to post-patent-expiration strategy.